The mean of analysts' price targets for Globus Medical (GMED) points to a 25% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Investors looking for stocks in the Medical - Instruments sector might want to consider either Globus Medical (GMED) or Integer (ITGR). But which of these two stocks is more attractive to value investors?
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
| Health Care Equipment & Supplies Industry | Healthcare Sector | Keith W. Pfeil CEO | XFRA Exchange | 379577208 CUSIP |
| US Country | 6,000 Employees | - Last Dividend | - Last Split | 3 Aug 2012 IPO Date |
Globus Medical, Inc. is a prominent medical device company focused on innovating healthcare solutions for patients dealing with musculoskeletal disorders, serving both the United States and international markets. Since its inception in 2003, Globus Medical has been at the forefront of developing a wide range of medical devices aimed at improving the quality of life for patients suffering from a variety of conditions, including degenerative and congenital disorders, deformities, tumors, and trauma injuries. With its headquarters located in Audubon, Pennsylvania, Globus Medical has established a strong global presence, distributing its products through a mix of direct sales, distributor representatives, and independent sales agents.
Globus Medical, Inc. offers an extensive portfolio of products and solutions across multiple domains within the musculoskeletal treatment spectrum:
Apart from its direct contribution to improving patient outcomes with its products, Globus Medical also engages in the distribution of human cell, tissue, and cellular and tissue-based products, leveraging its extensive network to facilitate availability across its served markets.